Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fitusiran

fitusiran

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of fitusiran

3 trials tracked of fitusiran: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 120 citations.

3Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3
  1. Phase 3 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Completed · 120 cited
  2. Phase 3 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors Completed · 87 cited
  3. Phase 3 A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Completed · 41 cited

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds non-clotting factor therapies reduce bleeding in congenital hemophilia
Hematology Meta-analysis
Meta-analysis finds non-clotting factor therapies reduce bleeding in congenital hemophilia Can new therapies help people with hemophilia bleed less and live better?
This meta-analysis of 6 RCTs (397 participants) synthesizes evidence on non-clotting factor therapies for bleed prevention in congenital hem…
For people with hemophilia, frequent bleeding can disrupt daily life and cause pain.
Apr 16, 2026